Octreotide and pasireotide are both somatostatin analogs, but they represent two generations. Octreotide targets mainly one somatostatin receptor subtype; pasireotide was engineered to bind several. That difference explains both pasireotide's unique ability to treat Cushing's disease and its notably higher risk of raising blood sugar.
At a glance
| Octreotide | Pasireotide | |
|---|---|---|
| Generation | First-generation | Second-generation (multi-receptor) |
| Receptor binding | Mainly SSTR2 | SSTR1, 2, 3 and especially SSTR5 |
| Brand names | Sandostatin, Sandostatin LAR | Signifor, Signifor LAR |
| Cushing's disease | Not effective | Approved — lowers ACTH and cortisol |
| Acromegaly | First-line medical option | For cases not controlled by first-generation analogs |
| Hyperglycemia risk | Modest | High — a defining limitation |
| Shared risks | Gallstones, GI effects | Gallstones, GI effects |
The bottom line
Octreotide remains the workhorse first-generation somatostatin analog for acromegaly and neuroendocrine tumors, with a manageable side-effect profile. Pasireotide's broader receptor binding unlocks uses octreotide cannot reach — most importantly Cushing's disease and some resistant acromegaly — but at the cost of a much higher rate of hyperglycemia and new diabetes that requires active monitoring. In short: pasireotide is not a "better octreotide" but a different tool for harder problems. Both are FDA-approved and specialist-managed.
Frequently asked questions
Why does pasireotide work in Cushing's disease when octreotide doesn't?
The ACTH-secreting pituitary tumors of Cushing's disease express abundant SSTR5 receptors. Pasireotide binds SSTR5 strongly, so it can suppress the excess ACTH, while octreotide — which targets mainly SSTR2 — does not reach that target effectively.
Which has more side effects, octreotide or pasireotide?
Both share the class effects of gallstones and gastrointestinal upset, but pasireotide carries a substantially higher risk of hyperglycemia and new-onset diabetes because it suppresses insulin and incretin hormones more strongly. Blood-sugar monitoring is essential with pasireotide.
Is pasireotide a replacement for octreotide?
No. Pasireotide is used for specific situations octreotide cannot address, such as Cushing's disease and some acromegaly not controlled by first-generation analogs. Octreotide remains a first-line option for many patients, with a gentler effect on blood sugar.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2003. Peer-reviewed study
- Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm. 1989. Peer-reviewed study
- Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA Cancer J Clin. 2018. Peer-reviewed study
- Yang LP, Keating GM. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2010. Peer-reviewed study
- Saif MW, Parikh R, Ray D, et al.. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019. Peer-reviewed study
- Turner HE, Vadivale A, Keenan J, et al.. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999. Peer-reviewed study
- Chanson P, Boerlin V, Ajzenberg C, et al.. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf). 2000. Peer-reviewed study
- Tutuncu Y, Berker D, Isik S, et al.. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. 2012. Peer-reviewed study
- Turner HE, Lindsell DR, Vadivale A, et al.. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol. 1999. Peer-reviewed study
- Kiesewetter B, Pflüger FF, Melhorn P, et al.. Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol. 2025. Peer-reviewed study
- Wang L, Chen S, Wu M, et al.. Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases. Sci Rep. 2025. Peer-reviewed study
- Zhao Y, Tao Y, Zhu Y, et al.. Comparison of somatostatin analogues on glucose metabolism: A systematic review and network Meta-Analysis of randomized controlled trials. Endocrine. 2026. Peer-reviewed study
- Pivonello R, De Leo M, Cozzolino A, et al. The Treatment of Cushing's Disease. Endocr Rev. 2015. Peer-reviewed study
- Witek P, Bolanowski M, Krętowski A, et al. Pasireotide-induced hyperglycemia in Cushing's disease and Acromegaly: A clinical perspective and algorithms proposal. Front Endocrinol (Lausanne). 2024. Peer-reviewed study
- McKeage K. Pasireotide in Acromegaly: A Review. Drugs. 2015. Peer-reviewed study
- Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019. Peer-reviewed study